GSK chief defends profits made on back of swine flu crisisBMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c2385 (Published 29 April 2010) Cite this as: BMJ 2010;340:c2385
- Helen Mooney
Andrew Witty, chief executive of global drug company GlaxoSmithKline, has denied accusations that the company profiteered during the swine flu crisis. Last year the company made a pre-tax profit of more than $13bn (£8.5bn; €9.8).
In an interview on the BBC’s World Have Your Say programme on 26 April Mr Witty denied that the company had “charged the whole world” for a vaccine that may not have been necessary.
“We have spent $2.5bn over the last seven years preparing for this situation, I think we charged a very …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial